Reduction of Experimental Cerebral Malaria and Its Related Proinflammatory Responses by the Novel Liposome-Basedβ-Methasone Nanodrug

Chemokine Gene Expression during Fatal Murine Cerebral Malaria and Protection Due to CXCR3 Deficiency

(2014) J. Miu et al.   JOURNAL OF IMMUNOLOGY

Neuregulin-1 attenuates mortality associated with experimental cerebral malaria

(2014) Wesley Solomon et al.   Journal of Neuroinflammation

Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stagePlasmodium bergheiANKA

(2013) Jennifer Palomo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Functional Roles for C5a and C5aR but Not C5L2 in the Pathogenesis of Human and Experimental Cerebral Malaria

(2013) Hani Kim et al.   INFECTION AND IMMUNITY

The role of chemokines in severe malaria: more than meets the eye

(2013) LISA J. IOANNIDIS et al.   PARASITOLOGY

The specific, reversible JNK inhibitor SP600125 improves survivability and attenuates neuronal cell death in experimental cerebral malaria (ECM)

(2013) Sripada Santosh Anand et al.   PARASITOLOGY RESEARCH

Pharmacologic Inhibition of CXCL10 in Combination with Anti-malarial Therapy Eliminates Mortality Associated with Murine Model of Cerebral Malaria

(2013) Nana O. Wilson et al.   PLoS One

Glucocorticosteroids in Nano-Sterically Stabilized Liposomes Are Efficacious for Elimination of the Acute Symptoms of Experimental Cerebral Malaria

(2013) Judith H. Waknine-Grinberg et al.   PLoS One

Inflammatory Responses Associated with the Induction of Cerebral Malaria: Lessons from Experimental Murine Models

(2013) Diana S. Hansen   PLoS Pathogens

IFN- -Producing CD4+ T Cells Promote Experimental Cerebral Malaria by Modulating CD8+ T Cell Accumulation within the Brain

(2012) A. Villegas-Mendez et al.   JOURNAL OF IMMUNOLOGY

Insights into the regulation of protein abundance from proteomic and transcriptomic analyses

(2012) Christine Vogel et al.   NATURE REVIEWS GENETICS

Effective Adjunctive Therapy by an Innate Defense Regulatory Peptide in a Preclinical Model of Severe Malaria

(2012) A. H. Achtman et al.   Science Translational Medicine

Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria

(2011) Sarah J Higgins et al.   Expert Review of Anti-Infective Therapy

Anxiety-like behavior and proinflammatory cytokine levels in the brain of C57BL/6 mice infected with Plasmodium berghei (strain ANKA)

(2011) Aline Silva de Miranda et al.   NEUROSCIENCE LETTERS

CD8+ T Cells and IFN-γ Mediate the Time-Dependent Accumulation of Infected Red Blood Cells in Deep Organs during Experimental Cerebral Malaria

(2011) Carla Claser et al.   PLoS One

Fabrication Principles and Their Contribution to the Superior In Vivo Therapeutic Efficacy of Nano-Liposomes Remote Loaded with Glucocorticoids

(2011) Yuval Avnir et al.   PLoS One

Modulation of cerebral malaria by fasudil and other immune-modifying compounds

(2010) Judith H. Waknine-Grinberg et al.   EXPERIMENTAL PARASITOLOGY

Immune-Mediated Mechanisms of Parasite Tissue Sequestration during Experimental Cerebral Malaria

(2010) F. H. Amante et al.   JOURNAL OF IMMUNOLOGY

Murine cerebral malaria: the whole story

(2010) Nicholas H. Hunt et al.   TRENDS IN PARASITOLOGY

Cognitive Dysfunction Is Sustained after Rescue Therapy in Experimental Cerebral Malaria, and Is Reduced by Additive Antioxidant Therapy

(2010) Patricia A. Reis et al.   PLoS Pathogens

CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-γ-induced chemokines

(2008) Philippe E. Van den Steen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria

(2008) G. S. V. Campanella et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA